Modern Africa Today
SEE OTHER BRANDS

Your daily news update on Africa

Modern Africa Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Modern Africa Today.

Press releases published on May 14, 2025

Stallion Uranium Announces Failure to File Cease Trade Order

Stallion Uranium Announces Failure to File Cease Trade Order

VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) announces that the British Columbia Securities Commission (the "BCSC"), as the principal regulator of …

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported …

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has submitted a Citizen Petition with the U.S. Food and Drug Administration (FDA) calling on the Agency to evolve from historical approaches to the development …

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with …

Harfang réalise une nouvelle découverte aurifère et intercepte 7,0 g/t Au sur 18.0 m à Sky Lake, Ontario

Harfang réalise une nouvelle découverte aurifère et intercepte 7,0 g/t Au sur 18.0 m à Sky Lake, Ontario

MONTRÉAL, 14 mai 2025 (GLOBE NEWSWIRE) -- Harfang Exploration Inc. (TSX.V: HAR) (“Harfang” ou la “Société”) a le plaisir d’annoncer une nouvelle découverte aurifère ainsi que les premiers résultats de son programme inaugural de forage au diamant de l’hiver …

Benitec Biopharma Releases Third Quarter 2025 Financial Results

Benitec Biopharma Releases Third Quarter 2025 Financial Results

HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace …

Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases

Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases

Tisento to Present at the “Primary Mitochondrial Diseases” Therapeutic Development Workshop Hosted by the Reagan-Udall Foundation for the FDA on May 22, 2025 Tisento to Sponsor the First Externally Led Patient-Focused Drug Development Meeting Dedicated to …

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis will be joined by members of Ligand’s …

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

–FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– –ORLADEYO would be the first targeted oral prophylactic therapy for patients with HAE under the age of 12, if approved– RESEARCH TRIANGLE PARK, N.C., May 14, …

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor …

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments Anticipate topline data midyear from the Phase 2b clinical trial of BPL-003 in patients with treatment- …

Harfang Makes New Gold Discovery and Drills 7.0 g/t Au Over 18.0 m at Sky Lake, Ontario

Harfang Makes New Gold Discovery and Drills 7.0 g/t Au Over 18.0 m at Sky Lake, Ontario

MONTREAL, May 14, 2025 (GLOBE NEWSWIRE) -- Harfang Exploration Inc. (TSX.V: HAR) (“Harfang” or the “Company”) is pleased to announce a new gold discovery and the first batch of results from the maiden 2025 winter diamond drill program (“Winter Drilling”). …

Polpharma Group Calls for Urgent Action to Protect early equitable access to medicines for European patients

Polpharma Group Calls for Urgent Action to Protect early equitable access to medicines for European patients

WARSAW, Poland, May 14, 2025 (GLOBE NEWSWIRE) -- Polpharma Group, a leading pharmaceutical company, urges the European Union to take decisive action to conclude the pharmaceutical reform and strengthen Europe’s capacity to produce essential medicines. We …

Titan Mining Reports 37% Revenue Growth and Lower Costs in Q1 2025

Titan Mining Reports 37% Revenue Growth and Lower Costs in Q1 2025

VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Titan Mining Corporation (TSX: TI, OTCQB: TIMCF) ("Titan" or the "Company") today announced its financial and operating results for the quarter ended March 31, 2025. The Company delivered a 37% …

First Atlantic Nickel Extends Strike Length of RPM Zone Discovery by 400 Meters, Intersecting .23% Nickel Over 396 Meters in Fourth Drill Hole

First Atlantic Nickel Extends Strike Length of RPM Zone Discovery by 400 Meters, Intersecting .23% Nickel Over 396 Meters in Fourth Drill Hole

VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") is excited to report assay results from drill hole AN-24-05, the fourth and final hole of …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service